精彩内容近日,CDE官网显示,石药集团提交3.3类新药度普利尤单抗注射液临床申请获受理。原研产品2024年以超140亿美元的全球销售额加冕“自免药王”,而在国内市场,该产品2024年在中国三大终端六大市场(统计范围详见本文末)的销售额超过25亿元。度普利尤单抗是一种结合IL-4Rα并抑制IL-4和IL-13信号传导的全人源单克隆抗体,目前已在全球获批多项适应症,包括特应性皮炎、哮喘、慢性鼻-鼻窦炎...
Source Link精彩内容近日,CDE官网显示,石药集团提交3.3类新药度普利尤单抗注射液临床申请获受理。原研产品2024年以超140亿美元的全球销售额加冕“自免药王”,而在国内市场,该产品2024年在中国三大终端六大市场(统计范围详见本文末)的销售额超过25亿元。度普利尤单抗是一种结合IL-4Rα并抑制IL-4和IL-13信号传导的全人源单克隆抗体,目前已在全球获批多项适应症,包括特应性皮炎、哮喘、慢性鼻-鼻窦炎...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.